Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6906280 | 0.84 | HTR1A (0.61) | HTR2AHTR1ASMN1; SMN2ALDH1A1HTR2C | |
| SCHEMBL6797367 | 0.81 | HTR2A (0.43) | HTR2AHTR1ASMN1; SMN2HTR2CHRH1 | |
| SCHEMBL6777242 | 0.80 | HTR1A (0.42) | HTR2AHTR1AHTR2CDRD2HTR2B | |
| SCHEMBL6773488 | 0.79 | ADRA2A (0.50) | HTR1ADRD2 | |
| SCHEMBL11107203 | 0.76 | ADRA2A (0.55) | HTR2AHTR1ASMN1; SMN2HTR2CHRH1 | |
| SCHEMBL7038063 | 0.76 | HTR2A (0.42) | HTR2AHTR1ASMN1; SMN2HTR2CHRH1 | |
| Hydrochloric Acid SCHEMBL11104894 | 0.76 | HTR2C (0.54) | HTR2AHTR1ASMN1; SMN2HTR2CHRH1 | |
| SCHEMBL6321111 | 0.76 | HTR2C (0.45) | HTR2AHTR1ASMN1; SMN2ALDH1A1HTR2C | |
| SCHEMBL6990695 | 0.75 | DRD2 (0.48) | HTR2ASMN1; SMN2HTR2CHRH1LMNA | |
| SCHEMBL11107814 | 0.74 | DRD2 (0.56) | HTR2ASMN1; SMN2ALDH1A1HTR2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815448-B2 | FOR THERAPY OF OGNITIVE DEFICITS DUE TO AGING, STROKE, HEAD TRAUMA, ALZHEIMER'S DISEASE OR OTHER NEURODEGENERATIVE DISEASES, OR SCHIZOPHRENIA; ANXIETY, AGGRESSION AND STRESS, AND FOR THE CONTROL OF VARIOUS PHYSIOLOGICAL PHENOMENA | WYETH | 2004-11-09 | — | — | US | claimed |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2002-12-19 | — | — | US | claimed |
| WO-2002090362-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-14 | — | — | WO | claimed |
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | WYETH (US) | 2002-12-19 | — | — | US | disclosed |
| WO-2002090362-A1 | AZAHETEROCYCLYLMETHYL DERIVATIVES OF 7,8-DIHYDRO-1,6,9-TRIOXA-3-AZA-CYCLOPENTA[A]NAPHTHALENE AS 5-HT1A ANTAGONISTS | WYETH (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193365-A1 | Azaheterocyclylmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalene as 5-HT1A antagonists | HTR1A, HTR5A, HTR1D | HTR2A 7/4885HTR1A 1/4885SMN1; SMN2 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.